Unichem Labs gets USFDA approval for Tadalafil Tablets
Tadalafil tablets are a generic version of Eli Lilly's Cialis tablets. The drug is indicated for the treatment of erectile dysfunction (ED), the signs and symptoms of benign prostatic hyperplasia (BPH) and ED and the signs and symptoms of BPH (EDIBPH).
New Delhi: Unichem Laboratories recently announced that it has received final approval for its abbreviated new drug application (ANDA), Tadalafil tablets, 2.5 mg, 5 mg 10 mg and 20 mg from the United States Food and Drug Administration (USFDA).
Tadalafil tablets are a generic version of Eli Lilly's Cialis tablets. The drug is indicated for the treatment of erectile dysfunction (ED), the signs and symptoms of benign prostatic hyperplasia (BPH) and ED and the signs and symptoms of BPH (EDIBPH).
Also Read: Unichem Labs gets USFDA nod to market Allopurinol tablets
Net profit of Unichem Laboratories declined 99.83% to Rs 4.30 crore on 52.77% rise in net sales to Rs 244.76 crore in Q3 December 2018 over Q3 December 2017.
Unichem Laboratories is an international, integrated, specialty pharmaceutical company.
Also Read: Unichem Labs standalone net profit declines 99.83 per cent in Q3
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd